DNA Co. Intrexon Raises $17.4M

Biotech company Intrexon Corporation raised $17.4 million in Series D shares, according to an SEC filing. A group of 40 investors took part in the equity offering.

Housed at the Virginia Tech campus in Blacksburg, Va., Intrexon is developing DNA control systems to enhance the safety and efficacy of existing and emerging biological therapeutics.
Named in the filing were executive officers Randal J. Kirk, chief executive officer and chairman of the board; Thomas Reed, Ph.D., founder & chief science officer; Sunil Chada, Ph.D., senior vice president, translational medicine; Rick Sterling, chief financial officer; Ronald B. Herberman, M.D., chief medical officer - oncology; and Robert Beech, senior vice president, corporate development & communications. Directors named were Cesar L. Alvarez; Steven Frank; Larry Horner; Dean J. Mitchell; and Burton Sobel M.D.

While specific investors are not identified in the filing, Intrexon has reported $35 million in Series C-2 investment in previous years from New River Management, managed by Third Security, LLC., and NewVa Capital Partners, LP.

SEC filing: http://tinyurl.com/ye5lkq6.

By Citybizlist Staff'
Citybizlist Washington D.C.
March 5, 2010